Evidence map›Paper›PMID 23836028›Full record

ReviewPsychopharmacology2013

Spicing things up: synthetic cannabinoids.

Max Spaderna, Peter H Addy, Deepak Cyril D'Souza

Abstract readReview
In one paragraph

Review in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cardiac effects of 5F-Cumyl-PEGACLONE.International journal of legal medicine · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Max SpadernaDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, USA.
Peter H Addy
Deepak Cyril D'Souza

Funding

NEUROBIOLOGY OF CANNABIS EFFECTSR01DA012382 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2001 to 2009
$1.3M
GABA Deficits and Vulnerability to Cannabinoid-Induced PsychosisR21MH086769 · NIMH · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2009 to 2010
$374k
Cannabinoids, Neural Synchrony and Information ProcessingR21DA020750 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2007 to 2008
$354k
NIDA NIH HHS R01 DA012382NIDA NIH HHS R21 DA020750NIMH NIH HHS R21 MH086769
6 · The paper itself

Abstract

rationaleRecently, products containing synthetic cannabinoids, collectively referred to as Spice, are increasingly being used recreationally.

objectivesThe availability, acute subjective effects-including self-reports posted on Erowid-laboratory detection, addictive potential, and regulatory challenges of the Spice phenomenon are reviewed.

resultsSpice is sold under the guise of potpourri or incense. Unlike delta-9-tetrahydrocannabinol, the synthetic cannabinoids present in Spice are high-potency, high-efficacy, cannabinoid receptor full agonists. Since standard urine toxicology does not test for the synthetic cannabinoids in Spice, it is often used by those who want to avoid detection of drug use. These compounds have not yet been subjected to rigorous testing in humans. Acute psychoactive effects include changes in mood, anxiety, perception, thinking, memory, and attention. Adverse effects include anxiety, agitation, panic, dysphoria, psychosis, and bizarre behavior. Psychosis outcomes associated with Spice provide additional data linking cannabinoids and psychosis. Adverse events necessitating intervention by Poison Control Centers, law enforcement, emergency responders, and hospitals are increasing. Despite statutes prohibiting the manufacture, distribution, and sale of Spice products, manufacturers are replacing banned compounds with newer synthetic cannabinoids that are not banned.

conclusionsThere is an urgent need for better research on the effects of synthetic cannabinoids to help clinicians manage adverse events and to better understand cannabinoid pharmacology in humans. The reported psychosis outcomes associated with synthetic cannabinoids contribute to the ongoing debate on the association between cannabinoids and psychosis. Finally, drug detection tests for synthetic cannabinoids need to become clinically available.

Indexed as

AnimalsCannabinoidsDesigner DrugsHumansIllicit DrugsLegislation, DrugSubstance Abuse DetectionSubstance-Related DisordersCannabinoidsDesigner DrugsIllicit Drugs

Identifiers

PMID23836028
PMCPMC3799955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.